|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000126010 |
Summary for GRPR |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000126010 | Gene symbol | GRPR |
| Gene name | gastrin releasing peptide receptor | |
| HGNC | 4609 | |
| Entrez ID | 2925 | |
| Gene type | protein_coding | |
| Synonyms | GRPR|BB2|BB2R|BRS2 | |
| UniProtAcc | P30550 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for GRPR |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| GRPR | 6.73e+02 | 1.27e+00 | 2.38e-01 | 5.32e+00 | 1.03e-07 | 1.93e-07 | BRCA |
Top |
Sex-biased somatic mutation for GRPR |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for GRPR |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg26196133 | chrX:16123101 | CGI:chrX:15854092-15855639 | promoter | 6.51e-01 | 8.35e-01 | -3.16e+00 | 1.56e-03 | 1.20e-02 | -1.84e-01 |
| LGG | cg00117066 | chrX:16122311 | CGI:chrX:15854092-15855639 | promoter | 7.09e-01 | 8.85e-01 | -1.39e+01 | 1.07e-43 | 1.04e-42 | -1.76e-01 |
| LGG | cg04625528 | chrX:16122528 | CGI:chrX:15854092-15855639 | promoter | 6.94e-01 | 8.55e-01 | -1.29e+01 | 4.72e-38 | 4.24e-37 | -1.61e-01 |
| LGG | cg26196133 | chrX:16123101 | CGI:chrX:15854092-15855639 | promoter | 5.05e-01 | 7.02e-01 | -1.10e+01 | 2.54e-28 | 1.98e-27 | -1.97e-01 |
| THCA | cg04625528 | chrX:16122528 | CGI:chrX:15854092-15855639 | promoter | 7.12e-01 | 8.27e-01 | -1.01e+01 | 5.54e-24 | 3.74e-23 | -1.15e-01 |
| HNSC | cg00117066 | chrX:16122311 | CGI:chrX:15854092-15855639 | promoter | 6.06e-01 | 7.29e-01 | -7.71e+00 | 1.25e-14 | 1.87e-13 | -1.22e-01 |
| LUSC | cg00117066 | chrX:16122311 | CGI:chrX:15854092-15855639 | promoter | 6.37e-01 | 7.65e-01 | -6.72e+00 | 1.78e-11 | 1.49e-10 | -1.28e-01 |
| SKCM | cg00117066 | chrX:16122311 | CGI:chrX:15854092-15855639 | promoter | 7.66e-01 | 8.72e-01 | -1.06e+01 | 3.66e-26 | 3.26e-25 | -1.06e-01 |
| STAD | cg13016045 | chrX:16122250 | CGI:chrX:15854092-15855639 | promoter | 6.68e-01 | 7.69e-01 | -5.65e+00 | 1.64e-08 | 1.09e-07 | -1.01e-01 |
| STAD | cg00117066 | chrX:16122311 | CGI:chrX:15854092-15855639 | promoter | 5.18e-01 | 6.37e-01 | -5.01e+00 | 5.46e-07 | 3.30e-06 | -1.19e-01 |
| STAD | cg26196133 | chrX:16123101 | CGI:chrX:15854092-15855639 | promoter | 6.51e-01 | 7.83e-01 | -7.84e+00 | 4.34e-15 | 4.06e-14 | -1.33e-01 |
| LIHC | cg13016045 | chrX:16122250 | CGI:chrX:15854092-15855639 | promoter | 5.98e-01 | 7.71e-01 | -7.69e+00 | 1.46e-14 | 3.19e-13 | -1.73e-01 |
| LIHC | cg26196133 | chrX:16123101 | CGI:chrX:15854092-15855639 | promoter | 5.29e-01 | 7.40e-01 | -7.14e+00 | 9.55e-13 | 1.94e-11 | -2.11e-01 |
| KIRP | cg00117066 | chrX:16122311 | CGI:chrX:15854092-15855639 | promoter | 7.82e-01 | 9.04e-01 | -5.97e+00 | 2.31e-09 | 2.90e-08 | -1.22e-01 |
| PCPG | cg13016045 | chrX:16122250 | CGI:chrX:15854092-15855639 | promoter | 7.33e-01 | 8.67e-01 | -6.77e+00 | 1.28e-11 | 7.53e-11 | -1.34e-01 |
| PCPG | cg00117066 | chrX:16122311 | CGI:chrX:15854092-15855639 | promoter | 6.49e-01 | 8.19e-01 | -7.19e+00 | 6.49e-13 | 4.05e-12 | -1.70e-01 |
| PCPG | cg04625528 | chrX:16122528 | CGI:chrX:15854092-15855639 | promoter | 5.30e-01 | 7.21e-01 | -5.77e+00 | 7.76e-09 | 4.06e-08 | -1.91e-01 |
| PCPG | cg26196133 | chrX:16123101 | CGI:chrX:15854092-15855639 | promoter | 2.74e-01 | 4.03e-01 | -9.31e+00 | 1.34e-20 | 1.33e-19 | -1.29e-01 |
| PAAD | cg00117066 | chrX:16122311 | CGI:chrX:15854092-15855639 | promoter | 7.06e-01 | 8.10e-01 | -6.41e+00 | 1.49e-10 | 1.25e-09 | -1.05e-01 |
| READ | cg04625528 | chrX:16122528 | CGI:chrX:15854092-15855639 | promoter | 3.82e-01 | 4.83e-01 | -2.44e+00 | 1.46e-02 | 3.08e-02 | -1.02e-01 |
| GBM | cg13016045 | chrX:16122250 | CGI:chrX:15854092-15855639 | promoter | 7.17e-01 | 8.17e-01 | -2.39e+00 | 1.69e-02 | 3.28e-02 | -1.00e-01 |
| GBM | cg00117066 | chrX:16122311 | CGI:chrX:15854092-15855639 | promoter | 6.33e-01 | 8.30e-01 | -4.53e+00 | 5.96e-06 | 3.65e-05 | -1.97e-01 |
| GBM | cg04625528 | chrX:16122528 | CGI:chrX:15854092-15855639 | promoter | 6.14e-01 | 7.74e-01 | -3.31e+00 | 9.48e-04 | 3.84e-03 | -1.60e-01 |
| GBM | cg26196133 | chrX:16123101 | CGI:chrX:15854092-15855639 | promoter | 4.97e-01 | 7.26e-01 | -4.51e+00 | 6.36e-06 | 3.88e-05 | -2.28e-01 |
| LAML | cg00117066 | chrX:16122311 | CGI:chrX:15854092-15855639 | promoter | 7.80e-01 | 9.03e-01 | -6.28e+00 | 3.32e-10 | 1.49e-09 | -1.23e-01 |
| THYM | cg00117066 | chrX:16122311 | CGI:chrX:15854092-15855639 | promoter | 7.37e-01 | 8.77e-01 | -7.10e+00 | 1.23e-12 | 6.37e-12 | -1.40e-01 |
| MESO | cg00117066 | chrX:16122311 | CGI:chrX:15854092-15855639 | promoter | 5.10e-01 | 7.07e-01 | -3.21e+00 | 1.30e-03 | 6.37e-03 | -1.96e-01 |
| MESO | cg04625528 | chrX:16122528 | CGI:chrX:15854092-15855639 | promoter | 5.93e-01 | 6.97e-01 | -2.84e+00 | 4.52e-03 | 1.71e-02 | -1.04e-01 |
| UVM | cg26196133 | chrX:16123101 | CGI:chrX:15854092-15855639 | promoter | 5.76e-01 | 7.82e-01 | -3.45e+00 | 5.65e-04 | 1.79e-03 | -2.06e-01 |
| ACC | cg00117066 | chrX:16122311 | CGI:chrX:15854092-15855639 | promoter | 5.60e-01 | 7.94e-01 | -4.21e+00 | 2.59e-05 | 1.88e-04 | -2.34e-01 |
| ACC | cg04625528 | chrX:16122528 | CGI:chrX:15854092-15855639 | promoter | 4.70e-01 | 6.18e-01 | -2.45e+00 | 1.43e-02 | 3.06e-02 | -1.47e-01 |
| ACC | cg13016045 | chrX:16122250 | CGI:chrX:15854092-15855639 | promoter | 7.41e-01 | 9.17e-01 | -4.44e+00 | 9.09e-06 | 6.94e-05 | -1.75e-01 |
| ACC | cg26196133 | chrX:16123101 | CGI:chrX:15854092-15855639 | promoter | 3.92e-01 | 5.19e-01 | -2.24e+00 | 2.52e-02 | 3.88e-02 | -1.27e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LIHC | cg26196133 | chrX:16123101 | CGI:chrX:15854092-15855639 | promoter | 7.40e-01 | 8.46e-01 | 2.97e+00 | 2.98e-03 | 4.17e-03 | -1.06e-01 |
| CHOL | cg04625528 | chrX:16122528 | CGI:chrX:15854092-15855639 | promoter | 8.21e-01 | 6.93e-01 | 1.99e+00 | 4.65e-02 | 4.65e-02 | 1.28e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| THCA | cg04625528 | chrX:16122528 | CGI:chrX:15854092-15855639 | promoter | 7.12e-01 | 8.35e-01 | -5.80e+00 | 6.55e-09 | 8.19e-08 | -1.23e-01 |
| HNSC | cg00117066 | chrX:16122311 | CGI:chrX:15854092-15855639 | promoter | 6.06e-01 | 7.73e-01 | -2.28e+00 | 2.23e-02 | 2.95e-02 | -1.67e-01 |
| COAD | cg26196133 | chrX:16123101 | CGI:chrX:15854092-15855639 | promoter | 6.10e-01 | 7.82e-01 | -2.00e+00 | 4.58e-02 | 4.68e-02 | -1.73e-01 |
| LIHC | cg13016045 | chrX:16122250 | CGI:chrX:15854092-15855639 | promoter | 5.98e-01 | 8.07e-01 | -3.21e+00 | 1.35e-03 | 2.85e-03 | -2.09e-01 |
| LIHC | cg00117066 | chrX:16122311 | CGI:chrX:15854092-15855639 | promoter | 4.04e-01 | 6.12e-01 | -3.43e+00 | 6.00e-04 | 1.52e-03 | -2.08e-01 |
Top |
Exon skipping events with PSI in TCGA for GRPR |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for GRPR |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for GRPR |
| TFs related to GRPR. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BRCA | CTCFL | GRPR | 5.12e+00 | 1.81e-03 | 6.90e+00 | 9.98e-01 | Female-biased |
| BRCA | FOXL1 | GRPR | 7.93e+00 | 9.91e-01 | 6.63e+00 | 8.55e-03 | Male-biased |
| BRCA | ZNF225 | GRPR | 6.29e+00 | 9.98e-01 | 4.38e+00 | 1.46e-03 | Male-biased |
| ESCA | BCL11A | GRPR | 7.10e+00 | 9.93e-01 | 6.30e+00 | 6.69e-03 | Male-biased |
| MESO | FOXL1 | GRPR | 7.40e+00 | 9.83e-01 | 6.35e+00 | 1.70e-02 | Male-biased |
| SARC | FOXL1 | GRPR | 7.64e+00 | 9.86e-01 | 7.13e+00 | 1.39e-02 | Male-biased |
| SARC | ZNF225 | GRPR | 7.26e+00 | 9.89e-01 | 6.71e+00 | 1.12e-02 | Male-biased |
| SKCM | ZNF225 | GRPR | 7.08e+00 | 9.81e-01 | 6.24e+00 | 1.90e-02 | Male-biased |
| GRPR related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for GRPR |
| RBPs related to ES in GRPR. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| GRPR related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000126010 | AC005165.1,hsa-mir-211,GRPR | Tumor-specific sex-biased ceRNA | TCGA-LIHC |
| ENSG00000126010 | AC008549.1,hsa-mir-211,GRPR | Tumor-specific sex-biased ceRNA | TCGA-LIHC |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of GRPR |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000126010 | GRPR | C0011570 | Mental Depression | 1 | PSYGENET |
| ENSG00000126010 | GRPR | C0011581 | Depressive disorder | 1 | PSYGENET |
| ENSG00000126010 | GRPR | C0025261 | Memory Disorders | 1 | CTD_human |
| ENSG00000126010 | GRPR | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| ENSG00000126010 | GRPR | C0233794 | Memory impairment | 1 | CTD_human |
| ENSG00000126010 | GRPR | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
| ENSG00000126010 | GRPR | C0751292 | Age-Related Memory Disorders | 1 | CTD_human |
| ENSG00000126010 | GRPR | C0751293 | Memory Disorder, Semantic | 1 | CTD_human |
| ENSG00000126010 | GRPR | C0751294 | Memory Disorder, Spatial | 1 | CTD_human |
| ENSG00000126010 | GRPR | C0751295 | Memory Loss | 1 | CTD_human |
